Request Demo
Recent blog posts
Latest Hotspot
8 min read
CLDN2 Biologics Sequence Review Report 2026: Claudin-2 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CLDN5 Biologics Sequence Review Report 2026: Claudin-5 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
BACE2 Biologics Sequence Review Report 2026: Beta-secretase 2 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of BACE2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
BACE1 Biologics Sequence Review Report 2026: Beta-secretase 1 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of BACE1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CCL11 Biologics Sequence Review Report 2026: Eotaxin Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CCL11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ALK Biologics Sequence Review Report 2026: ALK tyrosine kinase receptor Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of ALK sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADGRF5 Biologics Sequence Review Report 2026: Adhesion G protein-coupled receptor F5 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of ADGRF5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NCT07517419 Doxorubicin Hydrochloride Neoplasm Metastasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07517419 clinical trial report covering Doxorubicin Hydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600122069 Albumin-Bound Paclitaxel Locally Advanced Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
ChiCTR2600122069 clinical trial report covering Albumin-Bound Paclitaxel, Phase 2, endpoints, sponsor, geography, readout timing and development white spac
Latest Hotspot
8 min read
ChiCTR2600122046 HLX-43 Advanced Pancreatic Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
ChiCTR2600122046 clinical trial report covering HLX-43, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600122034 Trastuzumab Ovarian Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
ChiCTR2600122034 clinical trial report covering Trastuzumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07518238 Bupivacaine liposome Brachydactyly, Type E Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07518238 clinical trial report covering Bupivacaine liposome, Phase 2, endpoints, sponsor, geography, readout timing and development white space.